Literature DB >> 6362688

Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension.

R Fagard, R Fiocchi, P Lijnen, J Staessen, E Moerman, A de Schaepdryver, A Amery.   

Abstract

Ketanserin (120 mg/day) or placebo was given orally to 14 patients with mild to moderate essential hypertension according to a double blind crossover protocol, each treatment period lasting six weeks. Resting intra-arterial pressure in the recumbent position was reduced from 150/84 to 141/77 mm Hg; the hypotensive effect persisted throughout an uninterrupted graded exercise test to the point of exhaustion. The haemodynamic effects were similar at rest and during exercise. Overall, systemic vascular resistance decreased by 14%, heart rate fell by 5%, but stroke volume and cardiac output increased. Mean pulmonary arterial pressure and capillary wedge pressure were not significantly affected, but pulmonary vascular resistance decreased by 15%. The pressor response to methoxamine was significantly reduced by ketanserin. Both plasma noradrenaline and adrenaline concentrations increased, plasma renin activity and angiotensin II concentration decreased, and plasma aldosterone concentration was unchanged. The data indicate that ketanserin induces arteriolar dilatation, possibly related to an alpha-1-antagonistic action and to a reduced circulating angiotensin II concentration. The haemodynamic response is complex, and an increase in cardiac output limits the hypotensive effect. There is no firm evidence of an effect on venous tone as cardiac filling pressures do not change.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6362688      PMCID: PMC481475          DOI: 10.1136/hrt.51.2.149

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  18 in total

1.  Radioimmunoassay of angiotensin II in unextracted plasma.

Authors:  P J Lijnen; A K Amery; R H Fagard; F H Katz
Journal:  Clin Chim Acta       Date:  1978-09-01       Impact factor: 3.786

2.  Cardioaccelerator action of angiotensin.

Authors:  S D NISHITH; L D DAVIS; W B YOUMANS
Journal:  Am J Physiol       Date:  1962-02

3.  Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range.

Authors:  M Da Prada
Journal:  Life Sci       Date:  1976-10-15       Impact factor: 5.037

4.  The effect of serotonin and potassium on corticosterone and aldosterone production by isolated zona glomerulosa cells of the rat adrenal cortex.

Authors:  S A Tait; J F Tait; J E Bradley
Journal:  Aust J Exp Biol Med Sci       Date:  1972-12

5.  Acute blood-pressure-lowering effect of ketanserin.

Authors:  J De Cree; H Verhaegen; J Symoens
Journal:  Lancet       Date:  1981-05-23       Impact factor: 79.321

6.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

7.  Direct radioimmunoassay of plasma aldosterone in normal subjects.

Authors:  P Lijnen; A Amery; R Fagard; P Corvol
Journal:  Clin Chim Acta       Date:  1978-03-15       Impact factor: 3.786

8.  Faster radioimmunoassay of angiotensin I at 37 degrees C.

Authors:  F Fyhrquist; L Puutula
Journal:  Clin Chem       Date:  1978-01       Impact factor: 8.327

9.  Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.

Authors:  J M Van Nueten; P A Janssen; J Van Beek; R Xhonneux; T J Verbeuren; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

10.  5-HT2-receptor blockade in the treatment of heart failure. A preliminary study.

Authors:  J C Demoulin; M Bertholet; D Soumagne; J L David; H E Kulbertus
Journal:  Lancet       Date:  1981-05-30       Impact factor: 79.321

View more
  17 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 2.  Influence of antihypertensive drugs on exercise capacity.

Authors:  R Fagard; J Staessen; L Thijs; A Amery
Journal:  Drugs       Date:  1993       Impact factor: 9.546

3.  Ketanserin combined with a beta-blocker or diuretic in essential hypertension. A multicentre study.

Authors:  C Bartoloni; P Dupont; H Feltkamp; C I Johnston; K Steinbach; H Zilcher; F Kaindl
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Ketanserin in the treatment of diabetes-associated hypertension.

Authors:  C Beretta-Piccoli
Journal:  Drugs       Date:  1988       Impact factor: 9.546

5.  Effects of ketanserin on systemic and regional haemodynamics in patients with essential hypertension.

Authors:  Y Ito; M Isaka; H Noda; Y Sato; T Fujita
Journal:  Drugs       Date:  1988       Impact factor: 9.546

6.  Role of endogenous serotonin in the regulation of blood pressure in patients with chronic renal failure.

Authors:  M Yamakado; M Nagano; M Umezu; H Tagawa; H Kiyose
Journal:  Drugs       Date:  1988       Impact factor: 9.546

7.  A double-blind randomised comparison of perindopril and ketanserin in the treatment of hypertension in elderly diabetic patients.

Authors:  J Woo; K S Woo; K H Or; C S Cockram; M G Nicholls
Journal:  Drugs Aging       Date:  1993 Nov-Dec       Impact factor: 3.923

8.  Comparison of ketanserin and celiprolol on regression of left ventricular hypertrophy in older hypertensive patients.

Authors:  G P Vyssoulis; E A Karpanou; C E Pitsavos; T K Kourtis; A A Paleologos; P K Toutouzas
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

9.  Effects of ketanserin on intraocular pressure.

Authors:  C Costagliola; M L Fasano; G Iuliano; L A Ferrara
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

10.  Effects of ketanserin on microhemodynamics and hemorheology in patients with essential hypertension.

Authors:  M Konishi; M Sakakura; N Tsushima
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.